Adaptive Biotechnologies (ADPT) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Cathie Wood's Ark Invest Loads Up On Beam Therapeutics, Nu Holdings: Offloads MercadoLibre, Adaptive Biotechnologies
BenzingaFeb 22 04:05 ET
Piper Sandler Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $11
Moomoo NewsFeb 20 06:31 ET · Ratings
Piper Sandler Sticks to Their Buy Rating for Adaptive Biotechnologies (ADPT)
TipRanksFeb 20 06:26 ET · Ratings
Insider Sale: CEO and Chairman of $ADPT Sells 211,160 Shares
Quiver QuantitativeFeb 18 20:31 ET
Adaptive Biotechnologies(ADPT.US) Officer Sells US$3.99 Million in Common Stock
Moomoo NewsFeb 18 20:27 ET
Insiders At Adaptive Biotechnologies Sold US$626k In Stock, Alluding To Potential Weakness
Simply Wall StFeb 18 12:26 ET

Comments

This_Guy

Dec 8, 2024 17:28

$Nektar Therapeutics (NKTR.US)$
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting
Positive
73% complete response rate at 6 months vs 50% for placebo
5.8-fold improvement in CD8+ CAR-T cell kinetics compared to placebo
Two patients converted from partial to complete response with NKTR-255
Results exceeded historical benchmark data of 41-44% comple...

1

This_Guy

Dec 8, 2024 17:27

$Adaptive Biotechnologies (ADPT.US)$
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
Positive
Phase 3 trial data shows clonoSEQ can help avoid unnecessary transplantation procedures in MCL patients
FELIX study demonstrated 84% treatment response rate with MRD <10⁻⁶
Evidence supports clonoSEQ's effectiveness in early detection of disease progression
Data validates test'...

3

Jaguar8

Dec 8, 2024 16:19

NEWS SATURDAY 12/7

$Adaptive Biotechnologies (ADPT.US)$
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
Adaptive Biotechnologies (ADPT) presented new data at the 66th ASH Annual Meeting showcasing the effectiveness of their clonoSEQ® test in measuring residual disease (MRD) for blood cancer treatment. Key findings from multiple studies demonstrate that achieving MRD lev...

1

Jaguar8

Aug 29, 2024 07:03

NEWS

$Adaptive Biotechnologies (ADPT.US)$
Adaptive Announces IVDR Certification for clonoSEQ® in European Union
Adaptive Biotechnologies (Nasdaq: ADPT) has announced that its clonoSEQ® test has received In Vitro Diagnostic Regulation (IVDR) 2017/746 Class C certification in the European Union. This makes clonoSEQ the first IVDR-certified test for detecting minimal residual disease (MRD) in patients with lymphoid malignancies. The certification allows for broad use in assessing MRD status and chang...

2

RiskGame

Jun 28, 2024 18:55

Good volume move up. Small caps like adaptive biotechnologies are moving after Nvidia and other big techs took a break.
Should see higher prices from here.

3

ADPT Adaptive Biotechnologies

Trade Overview

Capital Trend

News

Comments

Trending Stocks